IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism

被引:172
作者
Malmberg, KJ
Levitsky, V
Norell, H
de Matos, CT
Carlsten, M
Schedvins, K
Rabbani, H
Moretta, A
Söderström, K
Levitskaya, J
Kiessling, R
机构
[1] Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, Immune & Gene Therapy Lab, Stockholm, Sweden
[2] Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden
[3] Karolinska Hosp, Dept Obstet & Gynecol, S-17176 Stockholm, Sweden
[4] Univ Genoa, Dipartimento Med Sperimentale, Genoa, Italy
关键词
D O I
10.1172/JC1200215564
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
IFN-gamma regulates the immunogenicity of target cells by increasing their expression of HLA class I molecules. This facilitates the T cell receptor-mediated recognition by CD8(+) T cells but decreases target cell sensitivity to lysis by NK cells due to engagement of inhibitory NK receptors. In this study, short-term tumor cell lines from patients with advanced ovarian carcinomas were established. We demonstrate the paradoxical fmding that IFN-gamma treatment of these short-term ovarian carcinoma cell lines (OVACs) resulted in resistance of tumor cells to lysis by peptide- and allospecific CD8(+) T cells. Blocking experiments revealed that this phenomenon was dependent on enhanced inhibitory signalling via CD94/NKG2A receptors expressed on the effector cells. This was associated with increased expression of HLA-E mRNA and HLA-G at the protein level in IFN-gamma-treated OVACs. Furthermore, pulsing of untreated OVACs with the leader sequence peptide of HLA-G protected these cells from lysis by CTLs, thus mimicking the inhibitory effect of IFN-gamma. This study provides evidence that CD94/NKG2A receptors play an important role in regulating T cell activity against tumors and shows that IFN-gamma modulation of target cells may shift the balance of triggering and inhibitory signals to T cells, turning off their cytolytic activity.
引用
收藏
页码:1515 / 1523
页数:9
相关论文
共 58 条
[1]  
Bertone S, 1999, EUR J IMMUNOL, V29, P23, DOI 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO
[2]  
2-Y
[3]   Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis [J].
Borrego, F ;
Ulbrecht, M ;
Weiss, EH ;
Coligan, JE ;
Brooks, AG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) :813-818
[4]   The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9 [J].
Braud, V ;
Jones, EY ;
McMichael, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (05) :1164-1169
[5]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799
[6]   HLA-G and HLA-E: fundamental and pathophysiological aspects [J].
Carosella, ED ;
Paul, P ;
Moreau, P ;
Rouas-Freiss, N .
IMMUNOLOGY TODAY, 2000, 21 (11) :532-534
[7]  
Cerboni C, 2001, EUR J IMMUNOL, V31, P2926, DOI 10.1002/1521-4141(2001010)31:10<2926::AID-IMMU2926>3.0.CO
[8]  
2-2
[9]   A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells [J].
Colonna, M ;
Navarro, F ;
Bellon, T ;
Llano, M ;
Garcia, P ;
Samaridis, J ;
Angman, L ;
Cella, M ;
LopezBotet, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (11) :1809-1818
[10]   ENHANCED IN-VIVO GROWTH AND RESISTANCE TO REJECTION OF TUMOR-CELLS EXPRESSING DOMINANT-NEGATIVE IFN-GAMMA RECEPTORS [J].
DIGHE, AS ;
RICHARDS, E ;
OLD, LJ ;
SCHREIBER, RD .
IMMUNITY, 1994, 1 (06) :447-456